Download the Practo app for free

Get Rs. 200 HealthCash
Download the app now
Book instant appointments 24x7
Bookmark doctors for quick access
Consult online with a doctor in 60s
Free ₹200 worth HealthCash on app
Use HealthCash to order medicines, health products & much more
Get App
0

Poractant Alfa

Description

Poractant Alfa is lung surfactant used for the prevention and treatment of respiratory distress syndrome in premature babies. Close monitoring of heart rate and arterial oxygenation is recommended during treatment with this medicine.

Side effects

Major & minor side effects for Poractant Alfa

Bleeding from lungs

Decreased heartbeat

Decreased blood pressure

Uses of Poractant Alfa

What is it prescribed for?

Neonatal Respiratory Distress Syndrome

This medicine is used for the prevention and treatment of respiratory distress syndrome (RDS) in newborn babies. It occurs when the baby's lung function decreases which may lead to serious breathing difficulties.
Concerns

Commonly asked questions

  • Onset of action

    The amount of time required for this medicine to show its action is not clinically established.
  • Duration of effect

    The amount of time for which this medicine remains active in the body is not clinically established.
  • Safe with alcohol?

    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?

    No habit-forming tendencies were reported
  • Usage in pregnancy?

    This medicine is not recommended for use in pregnant women.
  • Usage while breast-feeding?

    This medicine is not recommended for use in breastfeeding women.

Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women.

Breast-feeding

This medicine is not recommended for use in breastfeeding women.

General warnings

Birth weight

Care must be taken for use in newborn babies with very low birth-weight due to an increase in the risk of pulmonary hemorrhage (bleeding from lungs) and other severe adverse effects. Close monitoring of heart rate and arterial oxygenation is recommended during treatment with this medicine.

Intratracheal administration

The medicine should be administered through intratracheal route only.

Mucous plugging

In newborns whose ventilation becomes notably impaired during or immediately after the therapy with this medicine may have mucus plugging of the endotracheal tube. Therefore, it is recommended to perform suctioning of all newborns to avoid endotracheal tube obstruction due to mucous plugging.

Missed Dose

Since this medicine is usually administered by a qualified healthcare professional in the clinical/hospital setting, the likelihood of a missed dose is very low.

Overdose

Since this medicine is administered in the hospital setting by a qualified healthcare professional, the likelihood of an overdose is very less. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.

Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Interaction with Medicine

Disease interactions

Disease

Information not available.

Food interactions

Information not available.

Lab interactions

Information not available.
This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. Inform the doctor about all the current medicines as well as medical conditions of your infants before beginning treatment with this medicine.

Miscelleneous

Usage does not depend on food timings

To be taken as instructed by doctor

Does not cause sleepiness

How it works

The medicine works by reducing the surface tension within the alveoli of the lungs and improves breathing.

Legal Status

Approved

Approved

Approved

Unknown

Classification

Category

Lung surfactants

Schedule

Schedule H

[Internet]. Resources.chiesiusa.com. 2018 [cited 27 December 2018]. Available from:

https://resources.chiesiusa.com/Curosurf/CUROSURF_PI.pdf

Curosurf ® (poractant alfa) Intratracheal Suspension [Internet]. Curosurf. 2018 [cited 27 December 2018]. Available from:

https://curosurf.com/

[Internet]. 2018 [cited 27 December 2018]. Available from:

https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB09113.pdf?1456694339

Poractant alfa - DrugBank [Internet]. Drugbank.ca. 2018 [cited 27 December 2018]. Available from:

https://www.drugbank.ca/drugs/DB09113

Curosurf - Summary of Product Characteristics (SmPC) - (eMC) [Internet]. Medicines.org.uk. 2018 [cited 27 December 2018]. Available from:

https://www.medicines.org.uk/emc/product/6450/smpc#INTERACTIONS
Something doesn’t feel right?
Report an error

Information on this page was last updated on 24 Apr 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.